CN113456648A - New application of tanshinone IIA sodium sulfonate and preparation thereof - Google Patents

New application of tanshinone IIA sodium sulfonate and preparation thereof Download PDF

Info

Publication number
CN113456648A
CN113456648A CN202110817166.2A CN202110817166A CN113456648A CN 113456648 A CN113456648 A CN 113456648A CN 202110817166 A CN202110817166 A CN 202110817166A CN 113456648 A CN113456648 A CN 113456648A
Authority
CN
China
Prior art keywords
tanshinone iia
sodium sulfonate
iia sodium
tablet
percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110817166.2A
Other languages
Chinese (zh)
Other versions
CN113456648B (en
Inventor
曹选超
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Provincial Peoples Hospital
Original Assignee
Henan Provincial Peoples Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Provincial Peoples Hospital filed Critical Henan Provincial Peoples Hospital
Priority to CN202110817166.2A priority Critical patent/CN113456648B/en
Publication of CN113456648A publication Critical patent/CN113456648A/en
Application granted granted Critical
Publication of CN113456648B publication Critical patent/CN113456648B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a tanshinone IIA sodium sulfonate preparation and application thereof in preparing a medicine for treating cardiovascular diseases. The daily dosage of the tanshinone IIA sodium sulfonate is 50-200mg, pharmacological experiments prove that the tanshinone IIA sodium sulfonate can obviously reduce the contents of TC, TG and LDL-C in the serum of a hyperlipidemic mouse, improve the content of HDL-C, and the dissolution of tanshinone tablets and the dissolution of related substances meet the requirements of pharmacopoeia.

Description

New application of tanshinone IIA sodium sulfonate and preparation thereof
Technical Field
The invention relates to a new application of tanshinone IIA sodium sulfonate, in particular to an application of tanshinone IIA sodium sulfonate in preparing a medicament for treating hyperlipemia and/or a medicament for reducing blood fat, belonging to the technical field of medicaments.
Background
Cardiovascular and cerebrovascular diseases are the general names of cardiovascular and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases of heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension and the like. The cardiovascular and cerebrovascular diseases are common diseases seriously threatening the health of human beings, particularly the middle-aged and old people over 50 years old, have the characteristics of high morbidity, high disability rate and high mortality, even if the most advanced and perfect treatment means at present are applied, more than 50 percent of cerebrovascular accident survivors can not completely take care of the life, the number of people dying from the cardiovascular and cerebrovascular diseases in each year in the world reaches 1500 thousands, and the people live at the first of various causes of death.
Hyperlipidemia (Hyperlipemia), also known as hyperlipidemia, dyslipidemia and hyperlipoproteinemia, refers to the condition that one or more lipid substances in blood plasma are higher than normal, including cholesterol, triglyceride, phospholipid and non-free fatty acid, which are mostly caused by abnormal fat metabolism or operation. The modern medicine refers to hyperlipemia as "dyslipidemia" and "hyperlipidemia". Blood lipids are insoluble in water, bind to specific proteins, and exist in plasma in the form of lipoproteins, so that dyslipidemia is often manifested as lipoprotein abnormality. Dyslipidemia is clinically classified into hypercholesterolemia (CH), hypertriglyceridemia (TG), combined hyperlipidemia, and hypohyperlipoproteinemia. Hyperlipidemia is insidious, gradually developed and systemic, if the lipid substances in blood are excessive, the lipid substances are gradually retained on the wall of an arterial blood vessel, so that the wall of the arterial blood vessel is thickened and hardened to form atherosclerosis, and thus a series of diseases such as coronary heart disease, cerebral embolism, carotid artery stenosis and the like are induced.
Disclosure of Invention
One of the purposes of the invention is to provide a new application of tanshinone IIA sodium sulfonate, namely the application of tanshinone IIA sodium sulfonate in preparing a medicament for treating hyperlipemia and/or a medicament for reducing blood fat.
The tanshinone IIA sodium sulfonate can be directly prepared into clinically acceptable dosage forms or prepared into clinically acceptable dosage forms by adding pharmaceutically adjuvants.
Preferably, the clinically acceptable dosage forms include, but are not limited to, tablets, capsules, granules, and oral liquids.
The second purpose of the invention is to provide the using amount of the tanshinone IIA sodium sulfonate, namely the daily using amount of the tanshinone IIA sodium sulfonate is 50-200 mg; preferably, the daily usage amount of the tanshinone IIA sodium sulfonate is 80-160 mg; further preferably, the daily usage amount of the tanshinone IIA sodium sulfonate is 100-120 mg.
The invention also aims to provide a tanshinone IIA sodium sulfonate tablet, which comprises the following components:
Figure BDA0003170577290000021
preferably, the tanshinone IIA sodium sulfonate tablet contains the following components:
Figure BDA0003170577290000022
specifically, the filler is one or more of starch, dextrin, powdered sugar, lactose, microcrystalline cellulose, pregelatinized starch, anhydrous calcium hydrogen phosphate, mannitol and sorbitol; preferably, the filler is a mixture of lactose, microcrystalline cellulose and sorbitol; further preferably, the ratio of the lactose to the microcrystalline cellulose to the sorbitol is 1:2-5: 1-3; most preferably, the ratio of lactose, microcrystalline cellulose and sorbitol is 1:3.5: 2.
The adhesive is one or more of hydroxypropyl methylcellulose, povidone K30 and polyethylene glycol;
the disintegrating agent is one or more of low-substituted hydroxypropyl methylcellulose, crospovidone or carboxymethyl starch sodium;
the glidant is one or more of fumed silica, silicon dioxide or talcum powder;
the lubricant is one or more of magnesium stearate, sodium stearyl fumarate, talcum powder and superfine silica gel powder.
Further, the tanshinone IIA sodium sulfonate tablet also comprises a coating layer.
Preferably, the coating layer comprises the following components:
70 to 90 percent of hydroxypropyl methyl cellulose
10 to 30 percent of titanium dioxide
1-2% of magnesium stearate.
Further preferably, the coating layer comprises the following components:
75 to 80 percent of hydroxypropyl methyl cellulose
20 to 30 percent of titanium dioxide
1 to 1.5 percent of magnesium stearate.
Compared with the prior art, the invention has the following remarkable technical effects:
pharmacological experiments prove that the contents of TC, TG and LDL-C in the serum of a mouse with hyperlipidemia treated by tanshinone IIA sodium sulfonate are obviously reduced, the content of HDL-C is obviously increased, and the effect is equivalent to that of the existing simvastatin product. In addition, the tanshinone IIA sodium sulfonate tablet prepared by the invention has good stability and rapid dissolution, and is suitable for clinical application.
FIG. 1: comparison of dissolution rates of examples
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention is further illustrated by the following examples, which are intended to be purely exemplary and are not intended to limit the scope of the invention, as various equivalent modifications of the invention will occur to those skilled in the art upon reading the present disclosure and fall within the scope of the appended claims.
Example 1 tanshinone IIA sodium sulfonate tablet
Figure BDA0003170577290000031
Coating layer:
hydroxypropyl methylcellulose 700mg
Titanium dioxide 300mg
Magnesium stearate 20 mg.
The preparation process comprises the following steps: taking the tanshinone IIA sodium sulfonate, lactose, microcrystalline cellulose, sorbitol hydroxypropyl methylcellulose, low-substituted hydroxypropyl methylcellulose and silicon dioxide according to the prescription amount, uniformly mixing by adopting an equivalent progressive method, granulating by a dry method, adding magnesium stearate into the mixed granules, uniformly mixing, tabletting, and coating, wherein the weight of the coating is increased by 3%.
Example 2 tanshinone IIA sodium sulfonate tablets
Figure BDA0003170577290000041
Coating layer:
hydroxypropyl methylcellulose 900mg
Titanium dioxide 100mg
Magnesium stearate 10 mg.
The preparation process is described with reference to example 1.
Example 3 tanshinone IIA sodium sulfonate tablet
Figure BDA0003170577290000042
Coating layer:
hydroxypropyl methylcellulose 750mg
Titanium dioxide 240mg
Magnesium stearate 10 mg.
The preparation process is described with reference to example 1.
Example 4 tanshinone IIA sodium sulfonate tablets
Figure BDA0003170577290000043
Figure BDA0003170577290000051
Coating layer:
hydroxypropyl methylcellulose 800mg
Titanium dioxide 200mg
Magnesium stearate 15 mg.
The preparation process is described with reference to example 1.
Comparative example 1 tanshinone IIA sodium sulfonate tablet
Figure BDA0003170577290000052
Comparative example 2 tanshinone IIA sodium sulfonate tablet
Figure BDA0003170577290000053
Coating layer:
hydroxypropyl methylcellulose 700mg
Titanium dioxide 300mg
Magnesium stearate 20 mg.
First, stability investigation
Taking the sodium tanshinone IIA sulfonate tablets obtained in the examples 1 to 4 and the comparative examples 1 to 2, carrying out an accelerated test for 6 months under the conditions of a temperature of 40 ℃ and a constant temperature and humidity box with a relative humidity of 75 +/-5%, detecting related substances and contents in 0 day, 1 month and 6 months respectively, and carrying out stability comparison on different samples.
Table 1: comparison of stability of samples at 40 ℃ and 75% RH
Figure BDA0003170577290000061
As can be seen from Table 1, the tanshinone IIA sodium sulfonate tablet prepared by the invention has good stability, and after an accelerated test, the related substances slowly increase, and the content is over 98 percent; the stability is clearly better than in comparative examples 1 and 2.
Second, determination of dissolution
The tablets obtained in examples 1 to 4 were sampled at 5min, 10min, 15min, 20min and 30min with 900ml of water as dissolution medium and 50 rpm. Taking a proper amount of the dissolution liquid, filtering, discarding the primary filtrate, and taking the secondary filtrate as a test solution; and timely supplementing the dissolution medium with the same temperature and volume; taking another appropriate amount of tanshinone IIA sodium sulfonate reference substance, precisely taking an appropriate amount, and diluting with dissolution medium to obtain a solution containing about 2 μ g of tanshinone IIA sodium sulfonate per 1 ml. Precisely measuring the sample solution and the reference solution by 50 μ l each, injecting into a liquid chromatograph, recording chromatogram, and calculating the elution amount of each tablet.
TABLE 2 dissolution of tablets in aqueous solution
Figure BDA0003170577290000071
As can be seen from Table 2, the dissolution rate of more than 95% in 30min is achieved within 1-4 times in the aqueous solution, and the dissolution rate is stable and the dissolution effect is good; the dissolution of comparative example 1 was fast, and the dissolution of comparative example 2 exhibited a burst phenomenon, and the dissolution effect was not satisfactory.
Pharmacological experiments
In order to verify the efficacy of tanshinone IIA sodium sulfonate in treating cardiovascular diseases, particularly hyperlipidemia or hypolipidemic aspects, the inventor carries out related pharmacodynamic experimental research. It should be noted that the medicines selected in the pharmacodynamic tests below are the medicines obtained by the representative formula and the preparation method thereof; the inventor also conducts pharmacodynamic experiments on the medicines obtained by the other formulas and the preparation methods, and the experimental results show that the medicines obtained by the other formulas and the preparation methods have the same or similar effects, but the medicines are not exhaustive due to space limitations.
In addition, the pharmacodynamic experiments described below only take the hyperlipidemia animal model as an example to verify the efficacy of the present invention, and other efficacies mentioned in the present invention, the inventor also made relevant pharmacodynamic experiments, and the experimental results show that the same or similar effects are achieved, and the experiments are not exhaustive.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
Blood lipid reducing effect of tanshinone IIA sodium sulfonate on hyperlipidemic mice
1 Material
1.1 animals:
kunming mouse, SPF grade, 18-22g, license number of experimental animal: SYXK (lu) 20180008, provided by lumnan pharmaceutical group ltd, was acclimatized for one week prior to the experiment.
1.2 drugs, reagents
1.2.1 medicaments
Tanshinone IIA sodium sulfonate tablet prepared by the method of example 1
Simvastatin tablets (national drug standard H20030705, Lu nan Beite pharmaceutical Co., Ltd.)
1.2.3 dosage
Tanshinone IIA sodium sulfonate: 15.6mg/kg (high dose), 13.0mg/kg (low dose)
Simvastatin tablets: 1.3mg/kg
2. Modeling, grouping and administering drugs
Taking 50 mice, and randomly dividing the mice into a blank group, a model group, a simvastatin group, a tanshinone IIA sodium sulfonate high-dose group and a tanshinone IIA sodium sulfonate low-dose group, wherein each group comprises 10 mice; feeding mice of each group with high-fat feed for 5 weeks except for feeding the blank group with common feed; after feeding for one week, except for the blank group and the model group, the mice in all the other groups are subjected to intragastric administration with the corresponding drugs, and the mice in the blank group and the model group are subjected to intragastric administration with distilled water in the same amount for continuous administration for 4 weeks.
3 observation index
After the last administration, the mice were fasted for 12h without water deprivation, and the eyeballs were removed to obtain blood, centrifuged, and the serum was separated. And (3) detecting the levels of TC, TG and HDL-C, LDL-C in serum by using the kit.
3.5 statistical treatment
Statistical analysis is carried out on the obtained data by adopting SPSS 22.0 software, and the data is measured
Figure BDA0003170577290000083
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the analysis between the two groups is carried out by adopting an independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
The contents of TC, TG and LDL-C in the serum of a mouse fed by the high-fat feed are obviously increased, and the content of HDL-C is obviously reduced (P is less than 0.01);
the contents of TC, TG and LDL-C in the serum of a mouse treated by the tanshinone IIA sodium sulfonate are obviously reduced, the content of HDL-C is obviously increased (P is less than 0.05 or P is less than 0.01), and the effect is not obviously different from that of a simvastatin tablet group (P is more than 0.05).
TABLE 1 comparison of TC, TG, HDL-C, LDL-C levels in serum of mice of each group: (
Figure BDA0003170577290000081
n＝10，mmol/L)
Figure BDA0003170577290000082
Figure BDA0003170577290000091
Note: in contrast to the blank group,@P＜0.05，*P＜0.01；
in contrast to the model set,△P＜0.05，#P＜0.01。

Claims (10)

1. application of tanshinone IIA sodium sulfonate in preparing medicine for treating hyperlipidemia and/or medicine for reducing blood lipid is provided.
2. The use as claimed in claim 1, wherein the tanshinone IIA sodium sulfonate can be prepared into clinically acceptable dosage forms directly or by adding pharmaceutically adjuvants.
3. The use of claim 2, wherein the clinically acceptable dosage forms include, but are not limited to, tablets, capsules, granules, oral liquids.
4. The use as in any of claims 1-3, wherein the daily amount of sodium tanshinone IIA sulfonate used is 50-200 mg; preferably, the daily usage amount of the tanshinone IIA sodium sulfonate is 80-160 mg; further preferably, the daily usage amount of the tanshinone IIA sodium sulfonate is 100-120 mg.
5. A tanshinone IIA sodium sulfonate tablet is characterized by comprising the following components:
Figure FDA0003170577280000011
preferably, the tanshinone IIA sodium sulfonate tablet contains the following components:
Figure FDA0003170577280000012
6. the tanshinone IIA sodium sulfonate tablet as claimed in claim 5, wherein the filler is one or more of starch, dextrin, sugar powder, lactose, microcrystalline cellulose, pregelatinized starch, anhydrous calcium hydrogen phosphate, mannitol, and sorbitol; preferably, the filler is a mixture of lactose, microcrystalline cellulose and sorbitol; further preferably, the ratio of the lactose to the microcrystalline cellulose to the sorbitol is 1:2-5: 1-3; most preferably, the ratio of lactose, microcrystalline cellulose and sorbitol is 1:3.5: 2.
7. The tanshinone IIA sodium sulfonate tablet as claimed in claim 5, wherein the binder is one or more of hypromellose, povidone K30, polyethylene glycol; the disintegrating agent is one or more of low-substituted hydroxypropyl methylcellulose, crospovidone or carboxymethyl starch sodium; the glidant is one or more of fumed silica, silicon dioxide or talcum powder; the lubricant is one or more of magnesium stearate, sodium stearyl fumarate, talcum powder and superfine silica gel powder.
8. The tanshinone IIA sodium sulfonate tablet as claimed in claim 5, wherein the tanshinone IIA sodium sulfonate tablet further comprises a coating layer.
9. The sodium tanshinone IIA sulfonate tablet as claimed in claim 8, wherein the coating layer comprises the following components:
70 to 90 percent of hydroxypropyl methyl cellulose
10 to 30 percent of titanium dioxide
1-2% of magnesium stearate.
10. The sodium tanshinone IIA sulfonate tablet as claimed in claim 9, wherein the coating layer comprises the following components:
75 to 80 percent of hydroxypropyl methyl cellulose
20 to 30 percent of titanium dioxide
1 to 1.5 percent of magnesium stearate.
CN202110817166.2A 2021-07-20 2021-07-20 New application of tanshinone IIA sodium sulfonate and preparation thereof Active CN113456648B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110817166.2A CN113456648B (en) 2021-07-20 2021-07-20 New application of tanshinone IIA sodium sulfonate and preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110817166.2A CN113456648B (en) 2021-07-20 2021-07-20 New application of tanshinone IIA sodium sulfonate and preparation thereof

Publications (2)

Publication Number Publication Date
CN113456648A true CN113456648A (en) 2021-10-01
CN113456648B CN113456648B (en) 2022-06-07

Family

ID=77881384

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110817166.2A Active CN113456648B (en) 2021-07-20 2021-07-20 New application of tanshinone IIA sodium sulfonate and preparation thereof

Country Status (1)

Country Link
CN (1) CN113456648B (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861069A (en) * 2006-05-11 2006-11-15 阿尔贝拉医药(中国)有限公司 Use of tanshinone type compounds for preparing medicines to treat high blood-fat disease
CN102040644A (en) * 2009-11-03 2011-05-04 刘力 Tanshinone derivative as well as preparation and application thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1861069A (en) * 2006-05-11 2006-11-15 阿尔贝拉医药(中国)有限公司 Use of tanshinone type compounds for preparing medicines to treat high blood-fat disease
CN102040644A (en) * 2009-11-03 2011-05-04 刘力 Tanshinone derivative as well as preparation and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张强等主编: "《药剂学》", 31 January 2005, 北京大学医学出版社 *

Also Published As

Publication number Publication date
CN113456648B (en) 2022-06-07

Similar Documents

Publication Publication Date Title
TW201731509A (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EP0255404A1 (en) Sustained release ibuprofen formulation
EP1888080A1 (en) Pharmaceutical compositions of a neuroactive steroid and usees thereof
WO2015139512A1 (en) Fluvastatin sodium pharmaceutical composition
CN101069675A (en) A method of alleviating signs and symptons of spasticity
CN110037994A (en) A kind of brufen quick-release and slow-release double-layer tablets and preparation method thereof
CN105073108A (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
TW200534859A (en) Disintegrating tablets comprising licarbazepine
CN113149945A (en) Serial lignan compounds, pharmaceutical compositions, preparation methods and applications thereof
CN113456648B (en) New application of tanshinone IIA sodium sulfonate and preparation thereof
CN102293759A (en) Dextral ibuprofen sustained release tablet preparation and preparation method thereof
CN115518066A (en) Pharmaceutical composition for treating anticoagulation and application
CN117503775A (en) Formulations, methods, kits and dosage forms for treating atopic dermatitis and improving stability of active pharmaceutical ingredient
KR101697773B1 (en) Modified release composition comprising doxofylline
CN105596312B (en) A kind of Dimemorfan phosphate capsule composition and preparation method thereof
CN106214646A (en) A kind of silybin meglumine preparation
CN114948883A (en) Digoxin micro tablet and preparation method thereof
WO2021129340A1 (en) Tandospirone pharmaceutical composition, preparation method therefor and use thereof
CN106344519A (en) Tandospirone enteric-coated mini-pill, and preparation method and application thereof
CN110152003B (en) Compound medicine for treating COPD and preparation method thereof
CN113876734B (en) Polyene phosphatidyl choline enteric-coated tablet and preparation process and application thereof
CN114917213B (en) Mental disorder therapeutic agent comprising amitriptyline and method for treating mental disorder
CN114588124B (en) Delayed release pharmaceutical composition
CN101129358B (en) Moguisteine sustained-release tablet and method of preparing the same
CN110013474A (en) The new application of fenofibrate and drug for new application

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant